Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial
for Recurrent Endometrial Carcinoma
Drug: Selumetinib
293 locations incl. Birmingham
Sponsor: National Cancer Institute (NCI)
Sex: Female·Age: 18+
Code: NCT05554328·Phase 2·Recruiting